Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18839566 | 0.82 | KMT2A (0.45) | KMT2ALMNAMAPTL3MBTL1ALDH1A1 | |
| SCHEMBL18839310 | 0.82 | KMT2A (0.45) | KMT2ALMNAMAPTL3MBTL1ALDH1A1 | |
| SCHEMBL18839272 | 0.79 | MAPT (0.40) | KMT2ALMNAMAPTL3MBTL1ALDH1A1 | |
| SCHEMBL18839517 | 0.78 | BDKRB1 (0.38) | KMT2ALMNAMAPTL3MBTL1ALDH1A1 | |
| SCHEMBL8084639 | 0.77 | KMT2A (0.64) | KMT2ALMNAMAPTL3MBTL1ALDH1A1 | |
| SCHEMBL18839504 | 0.76 | RECQL (0.49) | KMT2ALMNAMAPTL3MBTL1ALDH1A1 | |
| SCHEMBL18839296 | 0.76 | KMT2A (0.41) | KMT2ALMNAMAPTALDH1A1CYP3A4 | |
| SCHEMBL21903307 | 0.74 | KMT2A (0.40) | KMT2ALMNAMAPTL3MBTL1ALDH1A1 | |
| SCHEMBL29271643 | 0.72 | MAPT (0.39) | LMNAMAPTL3MBTL1ALDH1A1CYP3A4 | |
| SCHEMBL21903236 | 0.72 | MAPT (0.40) | KMT2ALMNAMAPTL3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108834415-B | Substituted tricyclic 1, 4-benzodiazepine derivatives as allosteric modulators of group II metabotropic glutamate receptors | 多曼治疗学公司 | 2021-12-24 | — | — | CN | disclosed |
| US-11008323-B2 | Substituted tricyclic 1,4-benzodiazepinone derivatives as allosteric modulators of group II metabotropic glutamate receptors | DOMAIN THERAPEUTICS (FR) | 2021-05-18 | — | — | US | disclosed |
| US-20180346468-A1 | SUBSTITUTED TRICYCLIC 1,4-BENZODIAZEPINONE DERIVATIVES AS ALLOSTERIC MODULATORS OF GROUP II METABOTROPIC GLUTAMATE RECEPTORS | DOMAIN THERAPEUTICS (FR) | 2018-12-06 | — | — | US | disclosed |
| EP-3374360-A1 | SUBSTITUTED TRICYCLIC 1,4-BENZODIAZEPINONE DERIVATIVES AS ALLOSTERIC MODULATORS OF GROUP II METABOTROPIC GLUTAMATE RECEPTORS | Mavalon Therapeutics Limited (GB) | 2018-09-19 | — | — | EP | disclosed |
| WO-2017081483-A1 | SUBSTITUTED TRICYCLIC 1,4-BENZODIAZEPINONE DERIVATIVES AS ALLOSTERIC MODULATORS OF GROUP II METABOTROPIC GLUTAMATE RECEPTORS | MAVALON THERAPEUTICS LIMITED (GB) | 2017-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180346468-A1 | SUBSTITUTED TRICYCLIC 1,4-BENZODIAZEPINONE DERIVATIVES AS ALLOSTERIC MODULATORS OF GROUP II METABOTROPIC GLUTAMATE RECEPTORS | GRM3, GRM1, GRM2 | KMT2A 1640/4885LMNA 4825/4885MAPT 2130/4885 |
| US-11008323-B2 | Substituted tricyclic 1,4-benzodiazepinone derivatives as allosteric modulators of group II metabotropic glutamate receptors | GRM3, GRM1, GRM2 | KMT2A 1640/4885LMNA 4825/4885MAPT 2130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.